{"id":"ery001","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"This approach leverages the natural properties of red blood cells to protect the encapsulated drugs from degradation and clearance, allowing for targeted release in hypoxic tumor environments where the drug is most needed.","oneSentence":"ERY001 encapsulates chemotherapeutic agents within red blood cells to enhance their delivery to tumors while reducing systemic toxicity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:51:42.478Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced solid tumors, including colorectal and pancreatic cancer"}]},"trialDetails":[{"nctId":"NCT03674242","phase":"PHASE2, PHASE3","title":"Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2)","status":"TERMINATED","sponsor":"ERYtech Pharma","startDate":"2019-06-13","conditions":"Triple Negative Breast Cancer","enrollment":27},{"nctId":"NCT01518517","phase":"PHASE2, PHASE3","title":"GRASPA (Erythrocytes Encapsulating L-asparaginase) in Patients With Relapse of Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"ERYtech Pharma","startDate":"2009-12","conditions":"Acute Lymphoblastic Leukemia, in Relapse","enrollment":85},{"nctId":"NCT02195180","phase":"PHASE2","title":"Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma","status":"COMPLETED","sponsor":"ERYtech Pharma","startDate":"2014-07","conditions":"Pancreatic Adenocarcinoma Metastatic","enrollment":141}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["L asparaginase encapsulated in erythrocytes"],"phase":"phase_2","status":"active","brandName":"ERY001","genericName":"ERY001","companyName":"ERYtech Pharma","companyId":"erytech-pharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ERY001 encapsulates chemotherapeutic agents within red blood cells to enhance their delivery to tumors while reducing systemic toxicity. Used for Advanced solid tumors, including colorectal and pancreatic cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}